मूलभूत आँकड़े
| LEI | 549300220Z2GHH33XL82 |
| CIK | 1425205 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Iovance Biotherapeutics, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 29, 2025 |
Exhibit 99.1 1 © 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. Corporate Overview August 2025 1 2 © 2025, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Priva |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 29, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| August 22, 2025 |
Calculation of Filing Fee Tables S-3 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwa |
|
| August 22, 2025 |
Up to $350,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) Up to $350,000,000 Common Stock We entered into an Amended and Restated Open Market Sale Agreement SM, dated August 22, 2025, or the Sale Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. |
|
| August 22, 2025 |
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM Exhibit 1.1 AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM August 22, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| August 19, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| August 19, 2025 |
Exhibit 99.1 Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., August 18, 2025 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developi |
|
| August 7, 2025 |
Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport |
|
| August 7, 2025 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 7, 2025 |
Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended. Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.Establishment, Purpose and Term of Plan. 1.1Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Date |
|
| August 7, 2025 |
Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., August 7, 2025 - Iovance Biotherapeutics, Inc. (NA |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| July 15, 2025 |
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer Exhibit 99.1 Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer SAN CARLOS, Calif., July 15, 2025 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl |
|
| May 8, 2025 |
Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Regi |
|
| May 8, 2025 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit |
|
| February 27, 2025 |
Subsidiaries of the Company.** Exhibit 21.1 Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. Iovance Biotherapeutics UK Ltd, a limited company formed under the la |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686 |
|
| February 27, 2025 |
Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue Guidance of $450M-$475M FY25 Cash Burn Anticipated to be Un |
|
| February 27, 2025 |
Exhibit 10.55 AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of November 15, 2024, by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and IOVANCE BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”), wit |
|
| February 27, 2025 |
Exhibit 10.31 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Amendment #4 Cooperative Research and Development Agreement # 02734 IC Principal Investigator: Steven A. Rosenberg, M.D., Ph.D. |
|
| February 27, 2025 |
Exhibit 10.43 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is ente |
|
| February 27, 2025 |
Exhibit 10.42 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is ente |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 27, 2025 |
Iovance Biotherapeutics, Inc. Dodd-Frank Clawback Policy.** Exhibit 97.1 IOVANCE BIOTherapeutics, Inc. DODD-FRANK CLAWBACK POLICY Iovance Biotherapeutics, Inc. (the “Company”) has adopted this clawback policy (this “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a person covered by this Policy, it shall be the only clawback policy applicable |
|
| February 27, 2025 |
Exhibit 10.54 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of November 15, |
|
| February 27, 2025 |
Iovance Biotherapeutics, Inc. Insider Trading Policy.** Exhibit 19.1 Iovance Biotherapeutics, Inc. Insider Trading Policy I.INTRODUCTION It is the policy of Iovance Biotechnologies, Inc. (the “Company”) that its employees and members of its Board of Directors comply fully with the insider trading securities laws and regulations of the United States, of the several states, and of foreign jurisdictions, wherever they are applicable. It is illegal for any |
|
| February 27, 2025 |
Exhibit 10.30 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Amendment #3 Cooperative Research and Development Agreement # 02734 IC Principal Investigator: Steven A. Rosenberg, M.D., Ph.D. |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 10, 2025 |
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer Exhibit 99.1 Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer SAN CARLOS, Calif., February 10, 2025 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company’s e |
|
| December 13, 2024 |
Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (filed herewith). EXHIBIT 99.1 IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT PLAN IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose. The Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan (as amended from time to time, the “Plan”) amends and restates, in its entirety, the Iovance Biotherapeutics, Inc. 2021 I |
|
| December 13, 2024 |
Filing Fee Table (filed herewith). Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 2,000,000 $ 16,500,000.00 0.0001531 $ 2,526.15 Tot |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 As filed with the Securities and Exchange Commission on December 13, 2024 Registration No. |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| November 14, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| November 8, 2024 |
Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview November 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the “Company,” “we,” “us,” or “our”) within the meaning of th |
|
| November 7, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Re |
|
| November 7, 2024 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| October 18, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / STATE STREET CORP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IOVANCE BIOTHERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 462260100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. |
|
| August 9, 2024 |
Filing Fee Table (filed herewith). Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 7,389,374 $ 7.49 $ 55,346,411.26 0.0001476 $ 8,169 |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| August 9, 2024 |
Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview August 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning of the |
|
| August 9, 2024 |
Filing Fee Table (filed herewith). Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 500,000 $ 7.49 $ 3,745,000.00 0.0001476 $ 552.76 T |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. |
|
| August 8, 2024 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., August 8, 2024 - Iovance Biother |
|
| August 8, 2024 |
Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport |
|
| August 8, 2024 |
Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended. Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.Establishment, Purpose and Term of Plan. 1.1.Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Dat |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| June 28, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 - Iovance Biotherapeutics, Inc. (NA |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 11, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 3, 2024 |
Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview May 31, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the “Company,” “we,” “U.S.,” or “our”) within the meaning of t |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 31, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| May 24, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 10, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc. |
|
| May 9, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi |
|
| May 9, 2024 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl |
|
| May 9, 2024 |
Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended. EXHIBIT 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport |
|
| May 9, 2024 |
Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan. Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT PLAN IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose. The Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan (as amended from time to time, the “Plan”) amends and restates, in its entirety, the Iovance Biotherapeutics, Inc. 2021 I |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 3, 2024 |
Exhibit 99.1 LEO SHUMACHER, derivatively on behalf of IOVANCE BIOTHERAPEUTICS, INC., Plaintiff, V. IAIN DUKES, D.PHIL., MARIA FARDIS, PH.D., ATHENA COUNTOURIOTIS, M.D., RYAN D. MAYNARD, MERRILL A. MCPEAK, WAYNE P. ROTHBAUM, and MICHAEL WEISER, M.D., PH.D., Defendants, -and-IOV ANCE BIOTHERAPEUTICS, INC., Nominal Defendant. C.A. No. 2020-1049-PAF NOTICE OF PENDENCY OF SETTLEMENT OF ACTION TO: ALL C |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 3, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| March 29, 2024 |
Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF IOVANCE BIOTHERAPEUTICS, INC. (a Delaware corporation) As adopted by the Board of Directors on March 28, 2024 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE. 1 1.2 OTHER OFFICES. 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS. 1 2.2 ANNUAL MEETING. 1 2.3 SPECIAL MEETING. 1 2.4 ADVANCE NOTICE PROCEDURES FOR |
|
| March 19, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / Quogue Capital LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.000041666 par value per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) Wayne P. Rothbaum Quogue Capital LLC 101 Central Park West Suite 1F New York, New York 10019 (212) 554 |
|
| March 4, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer SAN CARLOS, Calif., March 4, 2024 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| March 1, 2024 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 1, 2024 PERCEPTIVE ADVISORS LLC By: |
|
| March 1, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) February 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 29, 2024 |
Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 28, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 28, 2024 |
Iovance Biotherapeutics, Inc. Insider Trading Policy.** Exhibit 19.1 Iovance Biotherapeutics, Inc. Insider Trading Policy I.INTRODUCTION It is the policy of Iovance Biotechnologies, Inc. (the “Company”) that its employees and members of its Board of Directors comply fully with the insider trading securities laws and regulations of the United States, of the several states, and of foreign jurisdictions, wherever they are applicable. It is illegal for any |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686 |
|
| February 28, 2024 |
Iovance Biotherapeutics, Inc. Dodd-Frank Clawback Policy.** Exhibit 97.1 IOVANCE BIOTherapeutics, Inc. DODD-FRANK CLAWBACK POLICY Iovance Biotherapeutics, Inc. (the “Company”) has adopted this clawback policy (this “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a person covered by this Policy, it shall be the only clawback policy applicable |
|
| February 28, 2024 |
Exhibit 99.1 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Can |
|
| February 28, 2024 |
Subsidiaries of the Company.** Exhibit 21.1 Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. Iovance Biotherapeutics UK Ltd, a limited company formed under the la |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 21, 2024 |
23,014,000 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) 23,014,000 Shares Common Stock We are offering 23,014,000 shares of our common stock. Our common stock trades on The Nasdaq Global Market under the symbol “IOVA.” On February 16, 2024, the last reported sales price of our common stock on The Nasdaq Global Marke |
|
| February 21, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc. |
|
| February 20, 2024 |
Exhibit 1.1 23,014,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENT February 20, 2024 JEFFERIES LLC BARCLAYS CAPITAL INC. GOLDMAN SACHS & CO. LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o Goldman Sachs & Co. LLC 200 West Street New York, New Yo |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 16, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 20, 2024 |
Exhibit 99.1 Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock February 20, 2024 SAN CARLOS, Calif., February 20, 2024 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with |
|
| February 20, 2024 |
Exhibit 99.2 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 16, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning |
|
| February 20, 2024 |
Exhibit 99.1 Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif., February 16, 2024 - Iovance Biother |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 20, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 14, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 14, 2024 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2024 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 13, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Iovance Biotherapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 462260100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2024 |
IOVA / Iovance Biotherapeutics, Inc. / MHR FUND MANAGEMENT LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 25, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| January 26, 2024 |
Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 25, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning o |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| January 8, 2024 |
Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning of th |
|
| December 27, 2023 |
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer Exhibit 99.1 Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer December 27, 2023 SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today ann |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 27, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| November 17, 2023 |
DLA Piper LLP (US) 51 John F. Kennedy Parkway Suite 120 Short Hills, New Jersey 07078-2704 www.dlapiper.com Emilio Ragosa, Esq. [email protected] T 973.307.3004 F 973.215.2804 November 17, 2023 Attention: Ibolya Ignat, Senior Staff Accountant Li Xiao, Staff Accountant U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Wash |
|
| November 7, 2023 |
Exhibit 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.Establishment, Purpose and Term of Plan. 1.1.Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Dat |
|
| November 7, 2023 |
Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport |
|
| November 7, 2023 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| November 7, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 Positive Regulatory Feedback Supports Lifileucel Regulatory Submissions in Europe and Canada in 20 |
|
| October 27, 2023 |
IOVA / Iovance Biotherapeutics Inc / Quogue Capital LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.000041666 par value per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) Wayne P. Rothbaum Quogue Capital LLC 101 Central Park West Suite 1F New York, New York 10019 (212) 554 |
|
| September 15, 2023 |
Exhibit 99.1 U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS, Ca |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 15, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R. |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 16, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| August 18, 2023 |
Exhibit 99.1 Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1. Multicenter Phase II Trial Of LN - 145 TIL Cell Therapy Plus Pembrolizumab in Patients With ICI - Naïve Metastatic NSCLC Adam Schoenfeld 1 ; Kai He 2 ; Jason Chesney 3 ; Edward Garon 4 ; Jorge Nieva 5 ; Adrian Sacher 6 ; Sylvia Lee 7 ; Friedrich Graf Finckenstein 8 ; Rana Fiaz 8 ; Melissa Catlett 8 ; Guang C |
|
| August 18, 2023 |
Exhibit 99.2 1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate Overview August 16, 2023 1 2 © 2023, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning of |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| August 8, 2023 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 8, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for Potential Commercial Launch of Lifileucel as First Approved TIL Therapy in 2023 Post- |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 13, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| July 13, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock SAN CARLOS, Calif., July 13, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tum |
|
| July 11, 2023 |
Exhibit 99.2 Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock SAN CARLOS, CA, July 10, 2023 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced |
|
| July 11, 2023 |
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock SAN CARLOS, CA, July 10, 2023 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that it intends to off |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| July 11, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc. |
|
| July 11, 2023 |
20,000,000 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) 20,000,000 Shares Common Stock We are offering 20,000,000 shares of our common stock. Our common stock trades on The Nasdaq Global Market under the symbol “IOVA.” On July 7, 2023, the last reported sales price of our common stock on The Nasdaq Global Market was |
|
| July 11, 2023 |
Exhibit 1.1 20,000,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENT July 10, 2023 GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Iovance Biotherapeutics, Inc., a Delaware corporati |
|
| July 10, 2023 |
SUBJECT TO COMPLETION, DATED JULY 10, 2023 TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| July 10, 2023 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1. The jurisdiction where the Non-Delaware corporation first formed is Nevada. 2. The jurisdiction immediately prior to filing this Certificate is Nevada. 3. The date the Non-Delaware Corporation first formed is September |
|
| July 10, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in Post-Anti-PD-1 NSCLC Demonstrated a 26.1% Objective Response Rate (ORR) in Regi |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 16, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Iovance Biotherapeutics, Inc. |
|
| June 16, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc. |
|
| June 16, 2023 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM June 16, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 16, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) $450,000,000 Common Stock We entered into an Open Market Sales Agreement SM, dated June 16, 2023, or the Sales Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. The Sales Agreement superseded and replaced the |
|
| June 16, 2023 |
Form of Indenture (filed herewith). Exhibit 4.1 IOVANCE BIOTHERAPEUTICS, INC. INDENTURE Dated as of [·] [·] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01. Certain Terms Defined 1 Section 1.02. Other Definitions 6 Section 1.03. Rules of Construction 6 ARTICLE 2 SECURITY FORMS 7 Section 2.01. Forms Generally 7 Section 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 7 Section 2.03. Form of T |
|
| June 12, 2023 |
Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended. Exhibit 99.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1. Establishment, Purpose and Term of Plan. 1.1. Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Comp |
|
| June 12, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc. |
|
| June 12, 2023 |
As filed with the Securities and Exchange Commission on June 12, 2023 As filed with the Securities and Exchange Commission on June 12, 2023 Registration No. |
|
| June 12, 2023 |
As filed with the Securities and Exchange Commission on June 12, 2023 As filed with the Securities and Exchange Commission on June 12, 2023 Registration No. |
|
| June 12, 2023 |
Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 99.1 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1. Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing th |
|
| June 12, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc. |
|
| June 6, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| June 2, 2023 |
Exhibit 99.2 Proleukin Business (Carve-out from Clinigen Limited) Unaudited interim condensed combined carve-out financial statements Six months ended 31 December 2022 (Amounts expressed in United States Dollars) 2 Index to Unaudited Interim Condensed Combined Carve-out Financial Statements Unaudited Interim Condensed Combined Statement of Profit or Loss and Other Comprehensive Income 3 Unaudited |
|
| June 2, 2023 |
Exhibit 99.1 Proleukin Business (Carve-out from Clinigen Limited) Combined carve-out financial statements For the years ended 30 June 2022, 2021, and as at 1 July, 2020 (Amounts expressed in United States Dollars) 1 Index to Combined Carve-out Financial Statements Report of Independent Auditors ...................................................................................................... 2 |
|
| June 2, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements present the combination of the historical financial statements of Iovance Biotherapeutics, Inc. (the “Company” or “Iovance”), and Clinigen SP Limited (a carve-out of the Proleukin Business from Clinigen (defined below)), which is referred to as Proleuki |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File |
|
| May 30, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| May 10, 2023 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 10, 2023 |
As filed with the Securities and Exchange Commission on May 10, 2023 As filed with the Securities and Exchange Commission on May 10, 2023 Registration No. |
|
| May 10, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl |
|
| May 9, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS, Calif., May 9, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company de |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| April 19, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definit |
|
| March 27, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission to U.S. Food and Drug Administration SAN CARLOS, Calif., March 24, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has compl |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686 |
|
| February 28, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 SAN CARLOS, Calif., February 28, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymph |
|
| February 28, 2023 |
Subsidiaries of the Company.** Exhibit 21.1 Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. Iovance Biotherapeutics UK Ltd, a limited company formed under the la |
|
| February 17, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) February 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC |
|
| February 14, 2023 |
IOVA / Iovance Biotherapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2023 |
SC 13G/A 1 p23-0587sc13ga.htm IOVANCE BIOTHERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing o |
|
| February 9, 2023 |
IOVA / Iovance Biotherapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Iovance Biotherapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 462260100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IOVANCE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462260100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 23, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission |
|
| January 27, 2023 |
Exhibit 10.1 EXECUTION VERSION CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) the registrant customarily and actually treats that information as private or confidential. Dated January 2023 Option Agreement relating to the operations of the Proleukin Bu |
|
| January 23, 2023 |
Exhibit 99.1 Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in Anti-PD-1 Naïve |
|
| January 23, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 23, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| January 13, 2023 |
IOVA / Iovance Biotherapeutics Inc / Quogue Capital LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.000041666 par value per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) Wayne P. Rothbaum Quogue Capital LLC 101 Central Park West Suite 1F New York, New York 10019 (212) 554 |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| January 11, 2023 |
Exhibit 99.1 1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate OverviewJanuary 20231 2 © 2023, Iovance Biotherapeutics, Inc. Forward-Looking StatementsCertain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Privat |
|
| December 30, 2022 |
IOVA / Iovance Biotherapeutics Inc / MHR FUND MANAGEMENT LLC - SC 13G Passive Investment SC 13G 1 d277539dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 22, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| December 30, 2022 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that this Initial Statement on Schedule 13G with respect to the shares of Common Stock of Iovance Biotherapeutics, Inc., dated as of December 30, 2022, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in |
|
| November 18, 2022 |
Exhibit 99.1 PRIVILEGED AND CONFIDENTIAL Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma BLA Submission Ongoing with U.S. Food and Drug Administration SAN CARLOS, Calif., November 18, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to t |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| November 18, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc. |
|
| November 18, 2022 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM November 18, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Iovance Biotherapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s |
|
| November 18, 2022 |
Exhibit 99.2 Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting 31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow Up in C-144-01 Trial (Cohorts 2 and 4) 42% of Responses Lasted for 24+ Months SITC Update and KOL Panel Webcast Th |
|
| November 18, 2022 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-238724 PROSPECTUS SUPPLEMENT (To Prospectus dated May 27, 2020) $500,000,000 Common Stock We have entered into an Open Market Sales Agreement SM, or the Sales Agreement, dated November 18, 2022, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. This Sales Agreemen |
|
| November 18, 2022 |
Exhibit 99.3 1 © 2022, Iovance Biotherapeutics, Inc. © 2022, Iovance Biotherapeutics, Inc. Iovance Investor Event & KOL Roundtable Society for Immunotherapy of Cancer (SITC) Annual Meeting November 10, 2022 1 #SITC22 2 © 2022, Iovance Biotherapeutics, Inc. Agenda Introduction – Friedrich Graf Finckenstein , M.D., Chief Medical Officer, Iovance Presentation Summary C - 144 - 01 Study in Advanced Me |
|
| November 3, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22 SAN CARLOS, Calif., November 3, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor inf |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| November 3, 2022 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R. |
|
| September 12, 2022 |
Notice of Pendency of Settlement of Action, dated August 31, 2022. Exhibit 99.1 |
|
| August 29, 2022 |
Exhibit 99.2 1 ? 2022, Iovance Biotherapeutics, Inc. ? 2022, Iovance Biotherapeutics, Inc. Corporate Overview August 25, 2022 1 2 ? 2022, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are ?forward - looking statements? of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the ?Company,? ?we,? ?us,? or ?our?) within the meaning of |
|
| August 29, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter 2022 SAN CARLOS, Calif., August 25, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing n |
|
| August 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 25, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| August 4, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., August 4, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 4, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| August 4, 2022 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc. |
|
| August 4, 2022 |
Exhibit 10.2 ? IOVANCE BIOTHERAPEUTICS, INC. DEFERRED RESTRICTED STOCK UNIT NOTICE UNDER THE IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN, AS AMENDED Name of Grantee: This Notice evidences the award of Deferred Restricted Stock Units (each, a "DRSU," and collectively, the "DRSUs") of Iovance Biotherapeutics, Inc., a Delaware corporation (the "Company"), that have been granted to you pu |
|
| August 4, 2022 |
Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 10.1 ? IOVANCE BIOTHERAPEUTICS, INC. ? 2018 EQUITY INCENTIVE PLAN AS AMENDED ? 1. Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the ?Plan?) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the ?Company?), and its Affiliates attract and retain key personnel by providing them the |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 4, 2022 |
+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents +- ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| June 13, 2022 |
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors Exhibit 99.1 Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors SAN CARLOS, Calif., June 13, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to th |
|
| May 26, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study Biologics License Application (BLA) Submission Planned for August 2022 Conference Call and Webcast Today at 5:00 p.m. ET SAN CARLOS, Calif., May 26, 2022 - Iovance Bi |
|
| May 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| May 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 13, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp |
|
| May 13, 2022 |
1 © 2022, Iovance Biotherapeutics, Inc. Corporate Overview May 2022 1 Exhibit 99.1 1 ? 2022, Iovance Biotherapeutics, Inc. Corporate Overview May 2022 1 2 Forward - Looking Statements ? 2022, Iovance Biotherapeutics, Inc. Certain matters discussed in this presentation are ?forward - looking statements? of Iovance Biotherapeutics, Inc. (hereinafter referred to as the ?Company,? ?we,? ?us,? or ?our?) within the meaning of the Private Securities Litigation Reform Act o |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 5, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Planned in August 2022 SAN CARLOS, Calif., May 5, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral- |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl |
|
| April 29, 2022 |
Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF IOVANCE BIOTHERAPEUTICS, INC. (a Delaware corporation) As adopted by the Board of Directors on April 25, 2022 and to be effective on the first calendar day following the 2022 Annual Meeting of Stockholders to be held on or about June 10, 2022 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE. 1 1.2 OTHER OFFICES. 1 ARTICLE I |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E |
|
| April 27, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant??? Filed by a Party other than the Registrant??? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 5, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileucel in Combination with Pembrolizumab SAN CARLOS, Calif., April 5, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing n |
|
| April 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 5, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. |
|
| March 11, 2022 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc. |
|
| February 24, 2022 |
Exhibit 99.1 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings SAN CARLOS, Calif., February 24, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 24, 2022 |
? EXHIBIT 10.13 ? IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT PLAN ? ? IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose. The Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan (as amended from time to time, the ?Plan?) amends and restates, in its entirety, the Iovance Biotherapeutics, In |
|
| February 24, 2022 |
Exhibit 10.46 ? ? ? THIRD AMENDMENT TO LEASE AGREEMENT ? This Amendment to Lease Agreement (this "Third Amendment") is made and entered into as of the 9th day of November, 2021, by and between 300 ROUSE BOULEVARD, LLC, a Delaware limited liability company ("Landlord"), and IOVANCE BIOTHERAPEUTICS, INC., a Delaware corporation ("Tenant"). ? RECITALS ? WHEREAS, Landlord and Tenant entered into that |
|
| February 24, 2022 |
Subsidiaries of the Company.** Exhibit 21.1 ? Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
IOVA / Iovance Biotherapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
IOVA / Iovance Biotherapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Iovance Biotherapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 462260100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 4, 2022 |
IOVA / Iovance Biotherapeutics Inc / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 462260100 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IOVANCE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.000041666 (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IOVANCE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 12, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| January 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
|
| January 10, 2022 |
Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team Exhibit 99.1 Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team SAN CARLOS, Calif., January 10, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translat |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 4, 2021 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. |
